Get the Stockscreener App
3.78
8.03%
-0.33
Pre-market:
3.89
0.11
+2.91%
Cingulate Inc stock is traded at $3.78, with a volume of 124.37K.
It is down -8.03% in the last 24 hours and down -1.82% over the past month.
See More
Previous Close:
$4.11
Open:
$4.25
24h Volume:
124.37K
Relative Volume:
0.96
Market Cap:
$13.79M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.116
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-13.10%
1M Performance:
-1.82%
6M Performance:
-21.41%
1Y Performance:
-70.56%
1-Day Range:
$3.7535
$4.25
1-Week Range:
$3.7535
$4.44
52-Week Range:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.78 | 13.79M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate moves closer to ADHD drug submission By Investing.com - Investing.com South Africa
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating - TipRanks
Cingulate moves closer to ADHD drug submission - Investing.com India
Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301 - MarketScreener
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301 - TipRanks
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - GlobeNewswire
Breakthrough ADHD Treatment Clears Critical FDA Hurdle: Once-Daily Drug Shows Promise - Stock Titan
Roth Capital Issues Positive Outlook for Cingulate Earnings - Defense World
Roth Capital Estimates Cingulate’s Q1 Earnings (NASDAQ:CING) - Defense World
Cingulate (CING) to Release Quarterly Earnings on Monday - Defense World
Cingulate Inc. Reports 2024 Financial and Development Milestones - TipRanks
Cingulate Inc. Reports Full Year 2024, Fourth Quarter - GlobeNewswire
Cingulate's ADHD Drug Nears FDA Filing: Key Trial Results and $17.5M Cash Boost - Stock Titan
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved - Yahoo Finance
Cingulate (CING) Expected to Announce Quarterly Earnings on Monday - Defense World
CING: April Pre-NDA Meeting - Yahoo Finance
Cingulate Inc. adjusts executive compensation - MSN
HC Wainwright Reaffirms Buy Rating for Cingulate (NASDAQ:CING) - Defense World
Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301 - TipRanks
Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data - Streetwise Reports
Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents - Contemporary Pediatrics
Cingulate reports safety results from final Phase 3 trials for CTx-1301 - TipRanks
Cingulate Inc. Advances Towards FDA Approval for CTx-1301 - TipRanks
Cingulate reports promising phase 3 safety data for ADHD treatment By Investing.com - Investing.com Canada
Cingulate reports promising phase 3 safety data for ADHD treatment - Investing.com
Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 - Marketscreener.com
Cingulate Reports Safety Results from Final Phase 3 Trials - GlobeNewswire
Could This ADHD Drug Breakthrough End Multiple Daily Dosing? Cingulate's Phase 3 Results Point to Yes - StockTitan
What's Going On With Cingulate Shares Recently? - MSN
Cingulate (NASDAQ:CING) Trading Down 2.1% – Here’s Why - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright - MSN
Cingulate CEO cleared of charges, retains board confidence - Investing.com India
Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia
Q4 Earnings Forecast for Cingulate Issued By HC Wainwright - Defense World
Cingulate (NASDAQ:CING) Price Target Raised to $20.00 - Defense World
Brokers Issue Forecasts for Cingulate FY2025 Earnings - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Public company CEO concludes case alleging aggravated domestic battery - The Business Journals
Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com Australia
Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World
Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada
Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World
Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):